Brought to you by 
Novartis options antisense candidates from Akcea for up to $1.7bn; exercises option on AKCEA-APO(a)-LRx, returns AKCEA-APOCIII-LRx
03 Aug 2021
Executive Summary
Novartis AG entered an agreement for the exclusive worldwide option to develop and commercialize cardiovascular-related antisense candidates AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx from Ionis Pharmaceuticals Inc.'s Akcea Therapeutics Inc. division.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis options antisense candidates from Akcea for up to $1.7bn; exercises option on AKCEA-APO(a)-LRx, returns AKCEA-APOCIII-LRx
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice